Research ArticleClinical Investigation
Open Access

Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non–Small Cell Lung Cancer Patient Undergoing Anti–PD-1 Immunotherapy

Negar Omidvari, Jelena Levi, Yasser G. Abdelhafez, Yiran Wang, Lorenzo Nardo, Megan E. Daly, Guobao Wang and Simon R. Cherry
Journal of Nuclear Medicine August 2024, jnumed.123.267003; DOI: https://doi.org/10.2967/jnumed.123.267003

Article Figures & Data

Figures

  • Figure
  • FIGURE 1.
    FIGURE 1.

    Maximum-intensity projections of PET SUV images (50–60 min after injection) of 4 healthy subjects and 1 NSCLC patient scanned before and after therapy. BMI = body mass index; Sub = subject.

  • FIGURE 2.
    FIGURE 2.

    Time–activity curves of healthy organs of interest analyzed in all subjects, showing complete duration of 90-min dynamic scans. Sub = subject.

  • FIGURE 3.
    FIGURE 3.

    Time–activity curves of organs with focally high uptake pattern in all subjects, showing complete duration of 90-min dynamic scans. Meningioma time–activity curve was affected by head motion for times later than 30 min after injection. Sub = subject.

  • FIGURE 4.
    FIGURE 4.

    Transverse slices through LLL mass of subject 5, comparing initial [18F]FDG PET/CT 3.5 mo before therapy (A), contrast-enhanced CT 2 d before therapy (B), [18F]F-AraG PET/CT 1 d before therapy (C), [18F]F-AraG PET/CT 2 wk after therapy (D), and contrast-enhanced CT 3 mo after therapy (E).

  • FIGURE 5.
    FIGURE 5.

    Time–activity curves of 7 subregions of LLL mass and 4 mediastinal LNs, showing complete duration of 90-min dynamic scans. *Two enlarged LNs. Sub = subject.

  • FIGURE 6.
    FIGURE 6.

    Spearman rank correlation coefficients (rs) calculated between (SUV, VT), (SUVR, VT), and (SUVR, Embedded Image) (A), between (KLogan, VT) and (KLogan,Embedded Image) (B), and between (2T6P Ki, SUVR) and (2T5P Ki, SUVR) (C) in different organs of interest. Asterisks shown above individual bars show significance level of Spearman rank P values (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

  • FIGURE 7.
    FIGURE 7.

    Changes in 7 subregions of LLL tumor after therapy, using SUVmean or SUVR without kinetic modeling (A), KLogan from Logan plots or VT from 2T6P compartmental modeling as macroparameters with high identifiability (B), 2T6P rate constants between blood and first compartment (K1 and k2) (C), and 2T6P rate constants between first and second compartments (k3 and k4) (D).

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords